Pancreatic Cancer’s Hidden Weakness: Damaged Mitochondria May Be Its Achilles’ Heel

A simple mechanism, a powerful consequence: how mitochondrial damage fuels cancer and how to stop it.

A study published in Proceedings of the National Academy of Sciences, led by Erica Golemis and senior author Dario Altieri, identifies a new vulnerability in pancreatic cancer: damaged mitochondria can trigger inflammation that helps tumors survive.

When mitochondria send the wrong signal

The key player is Mic60, a protein that maintains mitochondrial structure. When Mic60 levels decrease, mitochondria become unstable and begin to leak double stranded RNA into the cell.

This leakage triggers a false alarm. The cell interprets it as a viral signal and activates inflammatory pathways, especially TLR3 and TRAF6. Instead of stopping cancer, this inflammation supports tumor growth and survival.

A vulnerability inside the tumor

Pancreatic cancer cells appear to depend on this mitochondrial driven inflammation. When researchers blocked this pathway in preclinical models, tumor growth was reduced, while normal cells were less affected.

This suggests a clear therapeutic opportunity: targeting a mechanism the tumor relies on.

Next steps toward potential therapies

Researchers are now focusing on two priorities:

Understanding how Mic60 damages mitochondrial membranes, allowing double stranded RNA to escape and initiate inflammation

Developing and evaluating TLR3 TRAF6 inhibitors as a potential new treatment approach

WMS Perspective

This study reinforces a key message: mitochondria are not passive. They actively drive inflammation and disease.

Strategic question

Can mitochondrial dysfunction be transformed into a precise therapeutic target in cancer?

This research suggests it can.

For more information click here

Read the news on LinkedIn